You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameClorazepate
Accession NumberDB00628  (APRD00881)
TypeSmall Molecule
GroupsApproved, Illicit
DescriptionA water-soluble benzodiazepine derivative effective in the treatment of anxiety. It has also muscle relaxant and anticonvulsant actions. [PubChem]
Structure
Thumb
Synonyms
7-chloro-2,3-dihydro-2,2-Dihydroxy-5-phenyl-1H-1,4-benzodiazepine-3-carboxylic acid
Clorazepate
Clorazepic acid
External Identifiers
  • Abbott 35616
  • AH 3232
  • CB 4306
  • Ro 6-6616
  • TR 19119
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Clorazepatecapsule3.75 mgoralAa Pharma Inc1990-12-31Not applicableCanada
Clorazepatecapsule7.5 mgoralAa Pharma Inc1990-12-31Not applicableCanada
Clorazepatecapsule15 mgoralAa Pharma Inc1990-12-31Not applicableCanada
Novo-clopate Cap 15mgcapsule15 mgoralNovopharm Limited1984-12-312015-10-26Canada
Novo-clopate Cap 3.75mgcapsule3.75 mgoralNovopharm Limited1984-12-312015-10-26Canada
Novo-clopate Cap 7.5mgcapsule7.5 mgoralNovopharm Limited1984-12-312015-10-26Canada
Tranxene Cap 15mgcapsule15 mgoralAbbott Laboratories, Limited1973-12-312003-08-01Canada
Tranxene Cap 3.75mgcapsule3.75 mgoralAbbott Laboratories, Limited1973-12-312003-08-01Canada
Tranxene Cap 7.5mgcapsule7.5 mgoralAbbott Laboratories, Limited1976-12-312003-08-01Canada
Tranxene T-tabtablet3.75 mg/1oralRECORDATI RARE DISEASES, INC.1972-06-23Not applicableUs
Tranxene T-tabtablet7.5 mg/1oralRECORDATI RARE DISEASES, INC.1972-06-23Not applicableUs
Tranxene T-tabtablet15 mg/1oralRECORDATI RARE DISEASES, INC.1972-06-23Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Clorazepate Dipotassiumtablet7.5 mg/1oralPd Rx Pharmaceuticals, Inc.2010-07-29Not applicableUs
Clorazepate Dipotassiumtablet3.75 mg/1oralMylan Pharmaceuticals Inc.1987-07-17Not applicableUs
Clorazepate Dipotassiumtablet7.5 mg/1oralRanbaxy Pharmaceuticals Inc.2005-01-14Not applicableUs
Clorazepate Dipotassiumtablet7.5 mg/1oralTaro Pharmaceuticals U.S.A., Inc.2000-04-27Not applicableUs
Clorazepate Dipotassiumtablet15 mg/1oralbryant ranch prepack2000-04-27Not applicableUs
Clorazepate Dipotassiumtablet7.5 mg/1oralRebel Distributors Corp2000-04-27Not applicableUs
Clorazepate Dipotassiumtablet15 mg/1oralPd Rx Pharmaceuticals, Inc.2005-01-14Not applicableUs
Clorazepate Dipotassiumtablet7.5 mg/1oralMylan Pharmaceuticals Inc.1987-07-17Not applicableUs
Clorazepate Dipotassiumtablet15 mg/1oralRanbaxy Pharmaceuticals Inc.2005-01-14Not applicableUs
Clorazepate Dipotassiumtablet15 mg/1oralTaro Pharmaceuticals U.S.A., Inc.2000-04-27Not applicableUs
Clorazepate Dipotassiumtablet7.5 mg/1oralContract Pharmacy Services Pa2011-03-29Not applicableUs
Clorazepate Dipotassiumtablet15 mg/1oralPd Rx Pharmaceuticals, Inc.2010-07-29Not applicableUs
Clorazepate Dipotassiumtablet7.5 mg/1oralREMEDYREPACK INC.2010-11-18Not applicableUs
Clorazepate Dipotassiumtablet3.75 mg/1oralbryant ranch prepack2000-04-27Not applicableUs
Clorazepate Dipotassiumtablet15 mg/1oralMylan Pharmaceuticals Inc.1987-07-17Not applicableUs
Clorazepate Dipotassiumtablet15 mg/1oralA S Medication Solutions Llc2000-04-27Not applicableUs
Clorazepate Dipotassiumtablet3.75 mg/1oralAmerican Health Packaging2014-07-31Not applicableUs
Clorazepate Dipotassiumtablet7.5 mg/1oralPd Rx Pharmaceuticals, Inc.2010-07-29Not applicableUs
Clorazepate Dipotassiumtablet3.75 mg/1oralTaro Pharmaceuticals U.S.A., Inc.2000-04-27Not applicableUs
Clorazepate Dipotassiumtablet7.5 mg/1oralbryant ranch prepack2005-01-14Not applicableUs
Clorazepate Dipotassiumtablet3.75 mg/1oralRebel Distributors Corp2000-04-27Not applicableUs
Clorazepate Dipotassiumtablet3.75 mg/1oralRanbaxy Pharmaceuticals Inc.2005-01-14Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AnksenSanovel
CalnerMedipharm
CloranxenTeva
Clorazepatumsanofi-aventis
ClozeneWeidar
DipotAsian
FluliumPharmasant
Gen-xeneAlra
JustumSandoz
ManotranMarch
MedipaxTecnifar
MendonAbbott Japan
PolizepPolipharm
TencilanFinadiet
TrancapT P Drug
Transenesanofi-aventis
Tranxensanofi-aventis
Tranxènesanofi-aventis
TranxeneLundbeck
Tranxilenesanofi-aventis
Tranxiliumsanofi-aventis
Zetran-5Masa Lab
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Clorazepate dipotassium
ThumbNot applicableDBSALT000953
Categories
UNIID51WO0G0L4
CAS number23887-31-2
WeightAverage: 314.723
Monoisotopic: 314.045819935
Chemical FormulaC16H11ClN2O3
InChI KeyInChIKey=XDDJGVMJFWAHJX-UHFFFAOYSA-N
InChI
InChI=1S/C16H11ClN2O3/c17-10-6-7-12-11(8-10)13(9-4-2-1-3-5-9)19-14(16(21)22)15(20)18-12/h1-8,14H,(H,18,20)(H,21,22)
IUPAC Name
7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepine-3-carboxylic acid
SMILES
OC(=O)C1N=C(C2=CC=CC=C2)C2=C(NC1=O)C=CC(Cl)=C2
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as 1,4-benzodiazepines. These are organic compounds containing a benzene ring fused to a 1,4-azepine.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzodiazepines
Sub Class1,4-benzodiazepines
Direct Parent1,4-benzodiazepines
Alternative Parents
Substituents
  • 1,4-benzodiazepine
  • Alpha-amino acid or derivatives
  • Benzenoid
  • 1,3-dicarbonyl compound
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl chloride
  • Secondary carboxylic acid amide
  • Lactam
  • Ketimine
  • Carboxamide group
  • Azacycle
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Carboxylic acid derivative
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Imine
  • Carbonyl group
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Also used as adjunctive therapy in the management of partial seizures and for the symptomatic relief of acute alcohol withdrawal.
PharmacodynamicsClorazepate is a member of the group of drugs called benzodiazepines. Pharmacologically, clorazepate has the characteristics of the benzodiazepines. It has depressant effects on the central nervous system. The primary metabolite, nordiazepam, quickly appears in the blood stream. Studies in healthy men have shown that clorazenate has depressant effects on the central nervous system. Since orally administered clorazepate dipotassium is rapidly decarboxylated to form nordiazepam, there is essentially no circulating parent drug.
Mechanism of actionBenzodiazepines bind nonspecifically to benzodiazepine receptors BNZ1, which mediates sleep, and BNZ2, which affects affects muscle relaxation, anticonvulsant activity, motor coordination, and memory. As benzodiazepine receptors are thought to be coupled to gamma-aminobutyric acid-A (GABAA) receptors, this enhances the effects of GABA by increasing GABA affinity for the GABA receptor. Binding of the inhibitory neurotransmitter GABA to the site opens the chloride channel, resulting in a hyperpolarized cell membrane that prevents further excitation of the cell.
Related Articles
AbsorptionRapidly absorbed following oral administration (bioavailability is 91%).
Volume of distributionNot Available
Protein bindingThe protein binding of nordiazepam in plasma is high (97-98%).
Metabolism

The drug is metabolized in the liver and excreted primarily in the urine. The primary metabolite, nordiazepam, is further metabolized by hydroxylation. The major urinary metabolite is conjugated oxazepam (3-hydroxynordiazepam), and smaller amounts of conjugated p-hydroxynordiazepam and nordiazepam are also found in the urine.

SubstrateEnzymesProduct
Clorazepate
Not Available
OxazepamDetails
Clorazepate
Not Available
3-hydroxynordiazepamDetails
Clorazepate
NordiazepamDetails
Clorazepate
Not Available
p-HydroxynordiazepamDetails
Route of eliminationThe drug is metabolized in the liver and excreted primarily in the urine.
Half lifeThe serum half-life is about 2 days. Nordiazepam, the primary metabolite, quickly appears in the blood and is eliminated from the plasma with an apparent half-life of about 40 to 50 hours.
ClearanceNot Available
ToxicityOral LD50 in rats is 1320 mg/kg. In monkeys, oral LD50 exceed 1600 mg/kg. Symptoms of overdose include confusion, coma, impaired coordination, sleepiness, and slowed reaction time.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9285
Blood Brain Barrier+0.8373
Caco-2 permeable+0.5909
P-glycoprotein substrateNon-substrate0.5597
P-glycoprotein inhibitor INon-inhibitor0.9328
P-glycoprotein inhibitor IINon-inhibitor0.9386
Renal organic cation transporterNon-inhibitor0.9049
CYP450 2C9 substrateNon-substrate0.7365
CYP450 2D6 substrateNon-substrate0.8745
CYP450 3A4 substrateNon-substrate0.5798
CYP450 1A2 substrateInhibitor0.7086
CYP450 2C9 inhibitorNon-inhibitor0.756
CYP450 2D6 inhibitorNon-inhibitor0.819
CYP450 2C19 inhibitorNon-inhibitor0.7451
CYP450 3A4 inhibitorNon-inhibitor0.8333
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8165
Ames testNon AMES toxic0.8311
CarcinogenicityNon-carcinogens0.659
BiodegradationNot ready biodegradable1.0
Rat acute toxicity1.9282 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9987
hERG inhibition (predictor II)Non-inhibitor0.9207
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Able laboratories inc
  • American therapeutics inc
  • Clonmel healthcare ltd
  • Gd searle llc
  • Mylan pharmaceuticals inc
  • Purepac pharmaceutical co
  • Quantum pharmics ltd
  • Sandoz inc
  • Usl pharma inc
  • Warner chilcott div warner lambert co
  • Watson laboratories inc
  • Lundbeck inc
  • Lederle laboratories div american cyanamid co
  • Ranbaxy laboratories ltd
  • Taro pharmaceuticals usa inc
  • Alra laboratories inc
Packagers
Dosage forms
FormRouteStrength
Capsuleoral15 mg
Capsuleoral3.75 mg
Capsuleoral7.5 mg
Tabletoral15 mg/1
Tabletoral3.75 mg/1
Tabletoral7.5 mg/1
Prices
Unit descriptionCostUnit
Tranxene t-tablet 15 mg5.41USD tablet
Tranxene-T 15 mg tablet5.08USD tablet
Tranxene t-tablet 7.5 mg3.99USD tablet
Tranxene-T 7.5 mg tablet3.6USD tablet
Tranxene t-tablet 3.75 mg3.21USD tablet
Tranxene-T 3.75 mg tablet3.04USD tablet
Clorazepate 15 mg tablet2.17USD tablet
Clorazepate Dipotassium 15 mg tablet1.27USD tablet
Clorazepate Dipotassium 7.5 mg tablet0.93USD tablet
Clorazepate 7.5 mg tablet0.79USD tablet
Clorazepate Dipotassium 3.75 mg tablet0.76USD tablet
Clorazepate 3.75 mg tablet0.73USD tablet
Apo-Clorazepate 15 mg Capsule0.4USD capsule
Apo-Clorazepate 7.5 mg Capsule0.2USD capsule
Apo-Clorazepate 3.75 mg Capsule0.15USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilityVery solubleNot Available
logP3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0248 mg/mLALOGPS
logP2.68ALOGPS
logP3.21ChemAxon
logS-4.1ALOGPS
pKa (Strongest Acidic)3.32ChemAxon
pKa (Strongest Basic)-0.64ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area78.76 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity82.68 m3·mol-1ChemAxon
Polarizability30.63 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Schmitt, J.; U.S. Patent 3,516,988; June 23, 1970.

General References
  1. Authors unspecified: Systematic review of the benzodiazepines. Guidelines for data sheets on diazepam, chlordiazepoxide, medazepam, clorazepate, lorazepam, oxazepam, temazepam, triazolam, nitrazepam, and flurazepam. Committee on the Review of Medicines. Br Med J. 1980 Mar 29;280(6218):910-2. [PubMed:7388368 ]
  2. McElhatton PR: The effects of benzodiazepine use during pregnancy and lactation. Reprod Toxicol. 1994 Nov-Dec;8(6):461-75. [PubMed:7881198 ]
External Links
ATC CodesNot Available
AHFS Codes
  • 28:24.08
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
7-NitroindazoleThe risk or severity of adverse effects can be increased when Clorazepate is combined with 7-Nitroindazole.
AcepromazineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Aceprometazine.
adipiplonThe risk or severity of adverse effects can be increased when Clorazepate is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Agomelatine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Clorazepate is combined with Alfentanil.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Clorazepate is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Clorazepate.
AminophyllineThe therapeutic efficacy of Clorazepate can be decreased when used in combination with Aminophylline.
AmiodaroneThe metabolism of Clorazepate can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Clorazepate is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Amitriptyline.
AmobarbitalThe risk or severity of adverse effects can be increased when Clorazepate is combined with Amobarbital.
AmoxapineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Clorazepate is combined with Amperozide.
AprepitantThe serum concentration of Clorazepate can be increased when it is combined with Aprepitant.
AripiprazoleThe risk or severity of adverse effects can be increased when Clorazepate is combined with Aripiprazole.
ArticaineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Asenapine.
AtazanavirThe metabolism of Clorazepate can be decreased when combined with Atazanavir.
AtomoxetineThe metabolism of Clorazepate can be decreased when combined with Atomoxetine.
AzaperoneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Azaperone.
AzelastineClorazepate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Clorazepate.
BaclofenThe risk or severity of adverse effects can be increased when Clorazepate is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Clorazepate is combined with Barbital.
BenzocaineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Benzocaine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Clorazepate is combined with Benzyl alcohol.
BexaroteneThe serum concentration of Clorazepate can be decreased when it is combined with Bexarotene.
BoceprevirThe metabolism of Clorazepate can be decreased when combined with Boceprevir.
BortezomibThe metabolism of Clorazepate can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Clorazepate can be decreased when it is combined with Bosentan.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Clorazepate is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Clorazepate.
BrimonidineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Clorazepate is combined with Bromazepam.
BrompheniramineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Clorazepate is combined with Brotizolam.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Clorazepate.
BuprenorphineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Buprenorphine.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Clorazepate.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Clorazepate.
ButacaineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Clorazepate is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Clorazepate is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Clorazepate is combined with Butethal.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Clorazepate.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Clorazepate.
CarbinoxamineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Clorazepate is combined with Carfentanil.
CarisoprodolThe risk or severity of adverse effects can be increased when Clorazepate is combined with Carisoprodol.
CeritinibThe serum concentration of Clorazepate can be increased when it is combined with Ceritinib.
CetirizineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Chloral hydrate.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Clorazepate.
ChlormezanoneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Chlormezanone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Chloroprocaine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Chlorphenamine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Clorazepate.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Chlorprothixene.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Chlorzoxazone.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Clorazepate.
CitalopramThe risk or severity of adverse effects can be increased when Clorazepate is combined with Citalopram.
ClarithromycinThe metabolism of Clorazepate can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Clorazepate can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Clorazepate is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Clorazepate is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Clorazepate is combined with clomethiazole.
ClomipramineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Clorazepate is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Clonidine.
ClotrimazoleThe metabolism of Clorazepate can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Clorazepate.
CobicistatThe metabolism of Clorazepate can be decreased when combined with Cobicistat.
CocaineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Cocaine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Clorazepate.
ConivaptanThe serum concentration of Clorazepate can be increased when it is combined with Conivaptan.
CrizotinibThe metabolism of Clorazepate can be decreased when combined with Crizotinib.
CyclizineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Cyclobenzaprine.
CyclosporineThe metabolism of Clorazepate can be decreased when combined with Cyclosporine.
CyproheptadineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Cyproheptadine.
DabrafenibThe serum concentration of Clorazepate can be decreased when it is combined with Dabrafenib.
DantroleneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Clorazepate.
DapoxetineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Dapoxetine.
DarunavirThe metabolism of Clorazepate can be decreased when combined with Darunavir.
DasatinibThe serum concentration of Clorazepate can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Clorazepate can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Clorazepate can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when Clorazepate is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Desflurane.
DesipramineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Desloratadine.
DetomidineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Detomidine.
DexamethasoneThe serum concentration of Clorazepate can be decreased when it is combined with Dexamethasone.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Dexbrompheniramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Dexmedetomidine.
DextromoramideThe risk or severity of adverse effects can be increased when Clorazepate is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Dextropropoxyphene.
DezocineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Dezocine.
DiazepamThe risk or severity of adverse effects can be increased when Clorazepate is combined with Diazepam.
DifenoxinThe risk or severity of adverse effects can be increased when Clorazepate is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Dihydrocodeine.
DihydroergotamineThe metabolism of Clorazepate can be decreased when combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Dihydromorphine.
DiltiazemThe metabolism of Clorazepate can be decreased when combined with Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Diphenoxylate.
DoramectinThe risk or severity of adverse effects can be increased when Clorazepate is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Clorazepate is combined with Doxepin.
DoxycyclineThe metabolism of Clorazepate can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Clorazepate.
DoxylamineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Clorazepate is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Clorazepate.
DronedaroneThe metabolism of Clorazepate can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Clorazepate.
DrotebanolThe risk or severity of adverse effects can be increased when Clorazepate is combined with Drotebanol.
DyclonineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Dyclonine.
DyphyllineThe therapeutic efficacy of Clorazepate can be decreased when used in combination with Dyphylline.
EcgonineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Clorazepate is combined with ECGONINE METHYL ESTER.
EfavirenzThe serum concentration of Clorazepate can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Clorazepate is combined with Efavirenz.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Clorazepate.
EntacaponeThe risk or severity of adverse effects can be increased when Clorazepate is combined with Entacapone.
EnzalutamideThe serum concentration of Clorazepate can be decreased when it is combined with Enzalutamide.
ErythromycinThe metabolism of Clorazepate can be decreased when combined with Erythromycin.
EscitalopramThe risk or severity of adverse effects can be increased when Clorazepate is combined with Escitalopram.
Eslicarbazepine acetateThe serum concentration of Clorazepate can be decreased when it is combined with Eslicarbazepine acetate.
EstazolamThe risk or severity of adverse effects can be increased when Clorazepate is combined with Estazolam.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Clorazepate.
EthanolClorazepate may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Clorazepate.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Clorazepate.
EthosuximideThe risk or severity of adverse effects can be increased when Clorazepate is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Clorazepate is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Ethyl loflazepate.
EthylmorphineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Clorazepate is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Clorazepate.
EtoperidoneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Etorphine.
EtravirineThe serum concentration of Clorazepate can be decreased when it is combined with Etravirine.
EzogabineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Fencamfamine.
FenfluramineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Clorazepate is combined with Fentanyl.
FexofenadineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Clorazepate is combined with Flibanserin.
FluconazoleThe metabolism of Clorazepate can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Clorazepate is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Clorazepate is combined with Flunitrazepam.
FluoxetineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Clorazepate is combined with Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Clorazepate.
FlurazepamThe risk or severity of adverse effects can be increased when Clorazepate is combined with Flurazepam.
FluspirileneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Fluticasone Propionate.
FluvoxamineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Fluvoxamine.
FluvoxamineThe metabolism of Clorazepate can be decreased when combined with Fluvoxamine.
FosamprenavirThe serum concentration of Clorazepate can be increased when it is combined with Fosamprenavir.
FosaprepitantThe serum concentration of Clorazepate can be increased when it is combined with Fosaprepitant.
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Clorazepate.
FosphenytoinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Clorazepate.
FospropofolThe risk or severity of adverse effects can be increased when Clorazepate is combined with Fospropofol.
Fusidic AcidThe serum concentration of Clorazepate can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Clorazepate is combined with Gabapentin.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Clorazepate is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Clorazepate is combined with Gamma Hydroxybutyric Acid.
GlutethimideThe risk or severity of adverse effects can be increased when Clorazepate is combined with Glutethimide.
GuanfacineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Clorazepate is combined with Halazepam.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Clorazepate.
HalothaneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Halothane.
HeroinThe risk or severity of adverse effects can be increased when Clorazepate is combined with Heroin.
HexobarbitalThe risk or severity of adverse effects can be increased when Clorazepate is combined with Hexobarbital.
HydrocodoneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Hydrocodone.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Clorazepate.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Clorazepate.
HydroxyzineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Hydroxyzine.
IdelalisibThe serum concentration of Clorazepate can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Iloperidone.
ImatinibThe metabolism of Clorazepate can be decreased when combined with Imatinib.
ImipramineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Imipramine.
IndalpineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Indalpine.
IndinavirThe metabolism of Clorazepate can be decreased when combined with Indinavir.
IsavuconazoniumThe metabolism of Clorazepate can be decreased when combined with Isavuconazonium.
IsofluraneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Isoflurane.
IsradipineThe metabolism of Clorazepate can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Clorazepate can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Clorazepate can be increased when it is combined with Ivacaftor.
KetamineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Ketamine.
KetazolamThe risk or severity of adverse effects can be increased when Clorazepate is combined with Ketazolam.
KetobemidoneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Ketobemidone.
KetoconazoleThe metabolism of Clorazepate can be decreased when combined with Ketoconazole.
LamotrigineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Lamotrigine.
LevetiracetamThe risk or severity of adverse effects can be increased when Clorazepate is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Levobupivacaine.
LevocabastineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Clorazepate is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Levomethadyl Acetate.
LevomilnacipranThe risk or severity of adverse effects can be increased when Clorazepate is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Clorazepate is combined with Levorphanol.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Clorazepate.
LithiumThe risk or severity of adverse effects can be increased when Clorazepate is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Clorazepate is combined with Lofentanil.
LopinavirThe metabolism of Clorazepate can be decreased when combined with Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Clorazepate.
LovastatinThe metabolism of Clorazepate can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Clorazepate.
Lu AA21004The risk or severity of adverse effects can be increased when Clorazepate is combined with Lu AA21004.
LuliconazoleThe serum concentration of Clorazepate can be increased when it is combined with Luliconazole.
LurasidoneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Clorazepate.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Maprotiline.
MeclizineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Medetomidine.
MefloquineThe therapeutic efficacy of Clorazepate can be decreased when used in combination with Mefloquine.
MelatoninThe risk or severity of adverse effects can be increased when Clorazepate is combined with Melatonin.
MelperoneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Melperone.
MepivacaineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Mepivacaine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Clorazepate.
MesoridazineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Mesoridazine.
MetaxaloneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Metaxalone.
MethadoneClorazepate may increase the central nervous system depressant (CNS depressant) activities of Methadone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Clorazepate.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Methadyl Acetate.
MethapyrileneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Methaqualone.
MethocarbamolThe risk or severity of adverse effects can be increased when Clorazepate is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Clorazepate.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Methoxyflurane.
MethsuximideThe risk or severity of adverse effects can be increased when Clorazepate is combined with Methsuximide.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Clorazepate is combined with Methylphenobarbital.
MetyrosineClorazepate may increase the sedative activities of Metyrosine.
MianserinThe therapeutic efficacy of Clorazepate can be decreased when used in combination with Mianserin.
MidazolamThe risk or severity of adverse effects can be increased when Clorazepate is combined with Midazolam.
MifepristoneThe metabolism of Clorazepate can be decreased when combined with Mifepristone.
MilnacipranThe risk or severity of adverse effects can be increased when Clorazepate is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Clorazepate.
MirtazapineClorazepate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Clorazepate.
MitotaneThe serum concentration of Clorazepate can be decreased when it is combined with Mitotane.
ModafinilThe serum concentration of Clorazepate can be decreased when it is combined with Modafinil.
MolindoneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Molindone.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Clorazepate.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Clorazepate.
NabiloneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Nabilone.
NafcillinThe serum concentration of Clorazepate can be decreased when it is combined with Nafcillin.
NalbuphineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Nalbuphine.
NefazodoneThe metabolism of Clorazepate can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Clorazepate can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Clorazepate can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Clorazepate can be decreased when combined with Nevirapine.
NilotinibThe metabolism of Clorazepate can be decreased when combined with Nilotinib.
NitrazepamThe risk or severity of adverse effects can be increased when Clorazepate is combined with Nitrazepam.
Nitrous oxideThe risk or severity of adverse effects can be increased when Clorazepate is combined with Nitrous oxide.
NormethadoneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Nortriptyline.
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Clorazepate.
OlaparibThe metabolism of Clorazepate can be decreased when combined with Olaparib.
OlopatadineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Olopatadine.
OndansetronThe risk or severity of adverse effects can be increased when Clorazepate is combined with Ondansetron.
OpiumThe risk or severity of adverse effects can be increased when Clorazepate is combined with Opium.
OrlistatThe serum concentration of Clorazepate can be decreased when it is combined with Orlistat.
OrphenadrineClorazepate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Clorazepate.
OsanetantThe risk or severity of adverse effects can be increased when Clorazepate is combined with Osanetant.
OsimertinibThe serum concentration of Clorazepate can be increased when it is combined with Osimertinib.
OxazepamThe risk or severity of adverse effects can be increased when Clorazepate is combined with Oxazepam.
OxprenololThe risk or severity of adverse effects can be increased when Clorazepate is combined with Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Oxybuprocaine.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Clorazepate.
OxymorphoneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Oxymorphone.
PalbociclibThe serum concentration of Clorazepate can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Paliperidone.
ParaldehydeClorazepate may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Clorazepate.
ParoxetineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Paroxetine.
PentazocineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Pentazocine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Clorazepate.
PerampanelThe risk or severity of adverse effects can be increased when Clorazepate is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Clorazepate is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Perphenazine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Clorazepate.
PhenobarbitalThe risk or severity of adverse effects can be increased when Clorazepate is combined with Phenobarbital.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Clorazepate is combined with Phenoxyethanol.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Clorazepate.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Clorazepate.
PimozideThe risk or severity of adverse effects can be increased when Clorazepate is combined with Pimozide.
PipamperoneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Clorazepate is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Clorazepate is combined with Pomalidomide.
PosaconazoleThe metabolism of Clorazepate can be decreased when combined with Posaconazole.
PramipexoleClorazepate may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Clorazepate is combined with Prazepam.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Clorazepate.
PrilocaineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Prilocaine.
PrimidoneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Procaine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Clorazepate.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Clorazepate.
PromethazineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Promethazine.
ProparacaineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Proparacaine.
PropofolThe risk or severity of adverse effects can be increased when Clorazepate is combined with Propofol.
PropoxycaineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Propoxycaine.
ProtriptylineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when Clorazepate is combined with PSD502.
QuazepamThe risk or severity of adverse effects can be increased when Clorazepate is combined with Quazepam.
QuetiapineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Quetiapine.
RamelteonThe risk or severity of adverse effects can be increased when Clorazepate is combined with Ramelteon.
RanolazineThe metabolism of Clorazepate can be decreased when combined with Ranolazine.
RemifentanilThe risk or severity of adverse effects can be increased when Clorazepate is combined with Remifentanil.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Clorazepate.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Clorazepate.
RifabutinThe metabolism of Clorazepate can be increased when combined with Rifabutin.
RifampicinThe metabolism of Clorazepate can be increased when combined with Rifampicin.
RifapentineThe metabolism of Clorazepate can be increased when combined with Rifapentine.
RisperidoneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Risperidone.
RitonavirThe serum concentration of Clorazepate can be increased when it is combined with Ritonavir.
RomifidineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Romifidine.
RopiniroleClorazepate may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Clorazepate.
RotigotineClorazepate may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Clorazepate.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Clorazepate is combined with S-Ethylisothiourea.
SaquinavirThe serum concentration of Clorazepate can be increased when it is combined with Saquinavir.
ScopolamineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Clorazepate.
SertindoleThe risk or severity of adverse effects can be increased when Clorazepate is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Sevoflurane.
SildenafilThe metabolism of Clorazepate can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Clorazepate can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Clorazepate can be increased when it is combined with Simeprevir.
Sodium oxybateClorazepate may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Clorazepate.
St. John's WortThe serum concentration of Clorazepate can be decreased when it is combined with St. John's Wort.
StiripentolThe risk or severity of adverse effects can be increased when Clorazepate is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Clorazepate is combined with Sufentanil.
SulfisoxazoleThe metabolism of Clorazepate can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Clorazepate.
SuvorexantThe risk or severity of adverse effects can be increased when Clorazepate is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Clorazepate is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Clorazepate is combined with Tasimelteon.
TeduglutideThe serum concentration of Clorazepate can be increased when it is combined with Teduglutide.
TelaprevirThe metabolism of Clorazepate can be decreased when combined with Telaprevir.
TelithromycinThe metabolism of Clorazepate can be decreased when combined with Telithromycin.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Clorazepate.
TetrabenazineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Clorazepate is combined with Tetrodotoxin.
ThalidomideClorazepate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Clorazepate.
TheophyllineThe therapeutic efficacy of Clorazepate can be decreased when used in combination with Theophylline.
ThiamylalThe risk or severity of adverse effects can be increased when Clorazepate is combined with Thiamylal.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Clorazepate.
ThioridazineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Thioridazine.
ThiothixeneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Tiagabine.
TiclopidineThe metabolism of Clorazepate can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Tiletamine.
TizanidineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Tizanidine.
TocilizumabThe serum concentration of Clorazepate can be decreased when it is combined with Tocilizumab.
TolcaponeThe risk or severity of adverse effects can be increased when Clorazepate is combined with Tolcapone.
TopiramateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Topiramate.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Clorazepate.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Tranylcypromine.
TrazodoneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Clorazepate is combined with Triazolam.
TrifluoperazineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Trifluoperazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Clorazepate.
TrimipramineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Triprolidine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Clorazepate.
VenlafaxineThe metabolism of Clorazepate can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Clorazepate can be decreased when combined with Verapamil.
VigabatrinThe risk or severity of adverse effects can be increased when Clorazepate is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Vilazodone.
VoriconazoleThe metabolism of Clorazepate can be decreased when combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Xylazine.
YohimbineThe therapeutic efficacy of Clorazepate can be decreased when used in combination with Yohimbine.
ZaleplonThe risk or severity of adverse effects can be increased when Clorazepate is combined with Zaleplon.
ZiconotideThe risk or severity of adverse effects can be increased when Clorazepate is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Zimelidine.
ZiprasidoneThe metabolism of Clorazepate can be decreased when combined with Ziprasidone.
ZiprasidoneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Clorazepate is combined with Zolazepam.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Clorazepate.
ZonisamideThe risk or severity of adverse effects can be increased when Clorazepate is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Zopiclone.
ZotepineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Clorazepate is combined with Zuclopenthixol.
Food Interactions
  • Avoid alcohol.
  • Take without regard to meals.

Targets

Kind
Protein group
Organism
Human
Pharmacological action
yes
Actions
positive allosteric modulator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By similarity).
Components:
NameUniProt IDDetails
Gamma-aminobutyric acid receptor subunit alpha-1P14867 Details
Gamma-aminobutyric acid receptor subunit alpha-2P47869 Details
Gamma-aminobutyric acid receptor subunit alpha-3P34903 Details
Gamma-aminobutyric acid receptor subunit alpha-4P48169 Details
Gamma-aminobutyric acid receptor subunit alpha-5P31644 Details
Gamma-aminobutyric acid receptor subunit alpha-6Q16445 Details
Gamma-aminobutyric acid receptor subunit beta-1P18505 Details
Gamma-aminobutyric acid receptor subunit beta-2P47870 Details
Gamma-aminobutyric acid receptor subunit beta-3P28472 Details
Gamma-aminobutyric acid receptor subunit deltaO14764 Details
Gamma-aminobutyric acid receptor subunit epsilonP78334 Details
Gamma-aminobutyric acid receptor subunit gamma-1Q8N1C3 Details
Gamma-aminobutyric acid receptor subunit gamma-2P18507 Details
Gamma-aminobutyric acid receptor subunit gamma-3Q99928 Details
Gamma-aminobutyric acid receptor subunit piO00591 Details
Gamma-aminobutyric acid receptor subunit thetaQ9UN88 Details
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Cholesterol binding
Specific Function:
Can bind protoporphyrin IX and may play a role in the transport of porphyrins and heme (By similarity). Promotes the transport of cholesterol across mitochondrial membranes and may play a role in lipid metabolism (PubMed:24814875), but its precise physiological role is controversial. It is apparently not required for steroid hormone biosynthesis. Was initially identified as peripheral-type benz...
Gene Name:
TSPO
Uniprot ID:
P30536
Molecular Weight:
18827.81 Da
References
  1. Park CH, Carboni E, Wood PL, Gee KW: Characterization of peripheral benzodiazepine type sites in a cultured murine BV-2 microglial cell line. Glia. 1996 Jan;16(1):65-70. [PubMed:8787774 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Dresser GK, Spence JD, Bailey DG: Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet. 2000 Jan;38(1):41-57. [PubMed:10668858 ]
  2. Sachs B, Erdmann S, Al-Masaoudi T, Merk HF: In vitro drug allergy detection system incorporating human liver microsomes in chlorazepate-induced skin rash: drug-specific proliferation associated with interleukin-5 secretion. Br J Dermatol. 2001 Feb;144(2):316-20. [PubMed:11251565 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23